Design, Synthesis, and Evaluation of B-(Trifluoromethyl)phenyl Phosphine-Borane Derivatives as Novel Progesterone Receptor Antagonists.

All the reagents were purchased from Sigma-Aldrich Inc., St. Louis, MO, USA, Tokyo Chemical Industry Co., Ltd., Tokyo, Japan, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan, or Kanto Chemical Co., Inc., Tokyo, Japan, and used without further purification. Thin-layer chromatography (TLC) was performed using a silica gel coated with the fluorescent indicator F254 (Merck, Boston, MA, USA, #1.05715.0001). Silica gel column chromatography was performed using a neutral silica gel (60 Å, 40–50 μm) purchased from Kanto Chemical Co., Inc. NMR spectra were recorded using Bruker Avance 400 ( 1 H: 400 MHz, 13 C: 100 MHz, 11 B: 128 MHz, 19 F: 376 MHz, and 31 P: 161 MHz) and Bruker Avance 500 ( 1 H: 500 MHz and 13 C: 125 MHz) spectrometers. High-resolution mass (HRMS) spectra were recorded on a Bruker Daltonics micrOTOF-2 focus using electron spray ionization time-of-flight (ESI-TOF). A dry round-bottomed flask, equipped with a magnetic stirring bar, sealed with a septum, and protected with an Ar balloon, was charged with 4- or 3-(trifluoromethyl)phenyl boronic acid (190 mg, 1.0 mmol or 570 mg, 3.0 mmol) in 1.0 mL of THF. A solution of 1.0 M diisobutyl aluminium hydride (DIBAL) in toluene (3.0 or 5.0 mmol) was added to the mixture, and the corresponding phosphine was added at 0 °C. The mixture was stirred at room temperature and monitored using TLC. Once completed, the reaction was quenched by the addition of a saturated aqueous potassium sodium tartrate solution and extracted with AcOEt. The organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was evaporated, and the residue was purified using silica gel column chromatography (eluent = hexane/AcOEt) to generate the desired phosphine–borane derivatives. For compounds 20 – 22 and 32 – 34 , the corresponding phosphines were prepared immediately before addition, without purification. The details of the characterization and spectra of the compounds are presented in the Supporting Information . Colorless oil, Yield 67%, 154 mg; 1 H NMR (400 MHz, DMSO- d 6 ): δ 7.49–7.46 (m, 2H), 7.37–7.31 (m, 2H), 2.23–1.41 (br, 2H), 1.23 (d, J = 11.0 Hz, 9H); 11 B NMR (128 MHz, DMSO- d 6 ): δ −23.7 (d, J BP = 59.3 Hz); 13 C NMR (125 MHz, CDCl 3 ): δ 138.9 (d, J CP = 6.8 Hz), 131.74–131.66 (m), 129.1 (qd, J CF = 30.8 Hz, J CP = 3.3 Hz), 127.2 (d, J CP = 3.4 Hz), 125.0 (q, J CF = 272.2 Hz), 121.5–121.4 (m), 10.2 (d, J CP = 37.5 Hz); 19 F NMR (376 MHz, DMSO- d 6 ): δ −61.1 (s); 31 P NMR (161 MHz, DMSO- d 6 ): δ −6.1 (s); HRMS (ESI) m/z calcd. for C 10 H 15 BF 3 NaP [M + Na] + 257.0849, found 257.0852. White solid; Yield 68%, 177 mg; MP 75.0–75.8 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.65 (t, J = 8.7 Hz, 2H), 7.57–7.43 (m, 4H), 7.36–7.26 (m, 3H), 2.35–1.72 (br, 2H), 1.53 (d, J = 10.7 Hz, 6H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −23.8 (s); 13 C NMR (125 MHz, CDCl 3 ) δ 139.2 (d, J CP = 7.0 Hz), 132.1–132.0 (m), 131.3 (d, J CP = 2.4 Hz), 130.8 (d, J CP = 8.4 Hz), 129.3 (d, J CP = 53.5 Hz), 129.1 (qd, J CF = 31.0 Hz, J CP = 3.3 Hz), 128.9 (d, J CP = 10 Hz), 127.2 (d, J CP = 3.4 Hz), 124.9 (q, J CF = 272.1 Hz), 121.6–121.5 (m), 10.0 (d, J CP = 38.2 Hz; 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.1 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ −1.2 (s); HRMS (ESI) m/z calcd. for C 15 H 17 BF 3 NaP [M + Na] + 319.1005, found 319.0998. Colorless oil; Yield 26%, 71 mg; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.50–7.48 (m, 2H), 7.35–7.29 (m, 2H), 1.63–1.54 (m, 6H), 1.04–0.96 (m, 9H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −27.4 (d, J BP = 50.1 Hz); 13 C NMR (125 MHz, CDCl 3 ) δ 139.1 (d, J CP = 6.4 Hz), 132.0–131.9 (m), 129.0 (qd, J CF = 30.9 Hz, J CP = 3.0 Hz), 127.1 (d, J CP = 2.9 Hz), 125.0 (q, J CF = 272.3 Hz), 121.3–121.2 (m), 12.8 (d, J CP = 34.1 Hz), 6.4 (d, J CP = 3.9 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.1 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 12.5 (s); HRMS (ESI) m / z calcd. for C 13 H 21 BF 3 NaP [M + Na] + 299.1318, found 299.1325. White solid; Yield 68%, 215 mg; MP 40.0–40.5 °C; 1 H NMR (400 MHz, CD 2 Cl 2 ) δ 7.62–7.58 (m, 2H), 7.56–7.46 (m, 5H), 7.30 (d, J = 7.5 Hz, 1H), 7.23 (t, J = 7.5 Hz, 1H), 1.89–1.76 (m, 4H), 1.09–1.01 (m, 6H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −27.1 (s); 13 C NMR (100 MHz, DMSO- d 6 ): δ 139.8 (d, J CP = 6.4 Hz), 132.5 (d, J CP = 7.6 Hz), 131.9–131.7 (m), 131.7 (d, J CP = 2.2 Hz), 129.3 (d, J CP = 9.3 Hz), 128.2 (qd, J CF = 30.3 Hz, J CP = 3.1 Hz), 127.9 (d, J CP = 3.0 Hz), 126.4 (d, J CP = 51.1 Hz), 125.3 (q, J CF = 272.2 Hz), 121.5–121.4 (m), 14.5 (d, J CP = 36.0 Hz), 6.9 (d, J CP = 3.0 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.2 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 13.1 (s); ESMS (ESI) m / z calcd. for C 17 H 21 BF 3 NaP [M + Na] + 347.1318, found 347.1310. Colorless oil; Yield 54%, 514 mg (2 steps); 1 H NMR (400 MHz, DMSO- d 6 ) δ= 7.57–7.55 (m, 2H), 7.34–7.28 (m, 2H), 2.28–1.50 (br, 2H), 2.26–2.16 (m, 3H), 1.17–1.12 (m, 18H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.8 (s); 13 C NMR (125 MHz, DMSO- d 6 ) δ 140.2 (d, J CP = 5.5 Hz), 132.3–132.2 (m), 128.0 (qd, J CF = 30.2 Hz, J CP = 3.4 Hz), 127.9 (d, J CP = 3.0 Hz), 125.4 (q, J CF = 272.2 Hz), 121.31–121.25 (m), 20.6 (d, J CP = 29.5 Hz), 18.1 (d, J CP = 1.5 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.2 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 24.6 (s); HRMS (ESI) m/z calcd. for C 16 H 27 BF 3 NaP [M + Na] + 341.1788, found 341.1800. White solid; Yield 25%, 263 mg (2 step); MP 118.7–119.1 °C; 1 H NMR (400 MHz, CD 2 Cl 2 ) δ 7.80–7.76 (m, 2H), 7.69 (s, 1H), 7.62 (d, J = 6.9 Hz, 1H), 7.59–7.50 (m, 3H), 7.29 (d, J = 7.3 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 2.72–1.90 (br, 2H), 2.49–2.39 (m, 2H), 1.08–0.95 (m, 12H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.5 (s); 13 C NMR (100 MHz, DMSO- d 6 ) δ 140.2 (d, J CP = 6.8 Hz), 134.1 (d, J CP = 6.7 Hz), 132.3–132.2 (m), 132.0 (d, J CP = 2.2 Hz), 129.2 (d, J CP = 8.9 Hz), 128.2 (qd, J CF = 27.6 Hz, J CP = 2.5 Hz), 127.9 (d, J CP = 2.2 Hz), 125.4 (q, J CF = 272.2 Hz), 123.5 (d, J CP = 46.9 Hz), 121.53–121.46 (m), 20.7 (d, J CP = 32.7 Hz), 16.8–16.7 (m); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.2 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 22.1 (s); HRMS (ESI) m/z calcd. for C 19 H 25 BF 3 NaP [M + Na] + 375.1631, found 375.1653. Colorless oil; Yield 26%, 80 mg (2 steps); 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.54–7.52 (m, 2H), 7.34–7.26 (m, 2H), 2.00–1.05 (br, 2H), 0.80–0.62 (m, 15H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −29.1 (s); 13 C NMR (125 MHz, CDCl 3 ) δ 139.5 (d, J CP = 6.9 Hz), 132.5–132.4 (m), 128.7 (q, J CF = 31.4 Hz), 126.9 (d, J CP = 2.5 Hz), 125.0 (q, J CF = 272.3 Hz), 121.1–121.0 (m), 2.1 (d, J CP = 3.0 Hz), 1.6 (d, J CP = 58.3 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.1 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 17.3 (s); HRMS (ESI) m/z calcd. for C 16 H 21 BF 3 NaP [M + Na] + 335.1318, found 335.1323. Colorless oil; Yield 66%, 238 mg; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.47 (s, 2H), 7.36–7.30 (m, 2H), 1.57–1.51 (m, 6H), 1.38–1.29 (m, 12H), 0.85 (t, J = 7.0 Hz, 9H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −26.8 (s); 13 C NMR (125 MHz, CDCl 3 ) δ 139.0 (d, J CP = 6.4 Hz), 132.0–131.9 (m), 128.9 (qd, J CF = 30.8 Hz, J CP = 3.4 Hz), 127.1 (d, J CP = 3.4 Hz), 125.0 (q, J CF = 272.2 Hz), 121.2–121.1 (m), 24.4 (d, J CP = 2.8 Hz), 24.3 (d, J CP = 12.5 Hz), 20.2 (d, J CP = 33.0 Hz), 13.4 (s); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.2 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 7.03 (s); ESMS (ESI) m / z calcd. for C 19 H 33 BF 3 NaP [M + Na] + 383.2257, found 383.2276. Colorless oil; Yield 60%, 239 mg; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.56–7.53 (m, 2H), 7.32–7.26 (m, 2H), 2.23–1.69 (br, 2H), 2.19–2.10 (m, 3H), 1.81–1.79 (m, 6H), 1.58–1.50 (m, 18H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.4 (s); 13 C NMR (125 MHz, CDCl 3 ) δ 139.6 (d, J CP = 6.0 Hz), 132.8–132.7 (m), 128.7 (qd, J CF = 30.7 Hz, J CP = 2.9 Hz), 126.8 (d, J CP = 2.8 Hz), 125.0 (q, J CF = 272.3 Hz), 121.0–120.9 (m), 32.4 (d, J CP = 31.9 Hz), 28.3(s), 26.0 (d, J CP = 8.8 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.2 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 19.1 (s); HRMS (ESI) m/z calcd. for C 22 H 33 BF 3 NaP [M + Na] + 419.2257, found 419.2265. White solid; Yield:45%, 213 mg; MP 100.0–100.5 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.53 (s, 2H), 7.35–7.30 (m, 2H), 2.08–1.10 (br, 2H),1.94–1.65 (m, 18H), 1.32–1.14 (m, 15H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.8 (s); 13 C NMR (125 MHz, DMSO- d 6 ) δ 140.2 (d, J CP = 5.2 Hz), 132.4–132.3 (m), 128.0 (qd, J CF = 30.1 Hz, J CP = 2.6 Hz), 128.0 (d, J CP = 2.3 Hz), 125.5 (q, J CF = 272.6 Hz), 121.33–121.27 (m), 30.3 (d, J CP = 28.7 Hz), 27.8 (d, J CP = 1.4 Hz), 27.2 (d, J CP = 10.0 Hz), 26.1 (s); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.2 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 15.7 (s); HRMS (ESI) m/z calcd. for C 25 H 39 BF 3 NaP [M + Na] + 461.2727, found 461.2739. Colorless oil; Yield 31%, 109 mg; 1 H NMR (400 MHz, acetone- d 6 ) δ 7.65–7.60 (m, 2H), 7.35–7.28 (m, 2H), 4.26 (d, J = 357.0 Hz, 1H), 2.82–1.66 (br, 2H), 2.12–2.01 (m, 2H), 1.85–1.66 (m, 10H), 1.47–1.15 (m, 10H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −29.18 (s); 13 C NMR (100 MHz, acetone- d 6 ) δ 140.4 (d, J CP = 7.0 Hz), 132.8–132.7 (m), 129.5 (qd, J CF = 30.3 Hz, J CP = 2.9 Hz), 128.3 (d, J CP = 2.6 Hz), 126.2 (q, J CF = 271.5 Hz), 121.9–121.8 (m), 30.7 (s), 29.8 (d, J CP = 31.1 Hz), 29.1 (s), 27.4 (d, J CP = 10.3 Hz), 27.2 (d, J CP = 11.5 Hz), 26.5 (s); 19 F NMR (376 MHz, DMSO- d 6 ): δ −61.12 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 10.0 (d, J = 353.3 Hz); HRMS (ESI) m/z calcd. for C 19 H 29 BF 3 NaP [M + Na] + 379.1944, found 379.1929. Colorless oil; Yield:23%, 75 mg; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.57–7.53 (m, 2H), 7.33–7.527 (m, 2H), 2.52 (d, J = 9.1 Hz, 18H), 2.30–1.56 (br, 2H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −27.1 (d, J = 104.8 Hz); 13 C NMR (125 MHz, DMSO- d 6 ): δ 140.3 (d, J CP = 8.1 Hz), 132.3–132.2 (m), 127.8 (qd, J C F = 30.3 Hz, J CP = 2.9 Hz), 127.7 (s), 125.5 (q, J CF = 272.2 Hz), 121.18–121.12 (m), 37.3 (d, J CP = 3.4 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −61.1 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 92.3 (s); HRMS (ESI) m/z calcd. for C 13 H 24 BF 3 N 3 NaP [M + Na] + 344.1645, found 344.1640. Colorless oil; Yield: 24%, 55 mg; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.41 (s, 4H), 2.29–1.42 (br, 2H), 1.23 (d, J = 10.9 Hz, 9H); 11 B NMR (128 MHz, DMSO- d 6 ): δ −23.8 (d, J BP = 63.1 Hz); 13 C NMR (125 MHz, CDCl 3 ) δ 135.6 (d, J CP = 7.0 Hz), 126.8 (qd, J CF = 31.5 Hz, J CP = 4.7 Hz), 125.0 (qd, J CF = 271.3 Hz, J CP = 1.7 Hz), 123.7 (s), 10.3 (d, J CP = 37.5 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −55.9 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ −6.2 (s); HRMS (ESI) m/z calcd. for C 10 H 15 BF 3 NaP [M + Na] + 257.0849, found 257.0842. White solid; Yield:28%, 73 mg; MP 78.0–78.3 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.69–7.66 (m, 2H), 7.58–7.49 (m, 3H), 7.38 (s, 4H), 2.30–1.72 (br, 2H), 1.54 (d, J = 10.7 Hz, 6H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −23.8 (s); 13 C NMR (100 MHz, DMSO- d 6 ) δ 136.3 (d, J CP = 7.2 Hz), 131.6 (d, J CP = 2.1 Hz), 131.4 (d, J CP = 8.8 Hz), 130.1 (d, J CP = 54.4 Hz), 129.3 (d, J CP = 9.6 Hz), 125.7 (qd, J CF = 31.2 Hz, J CP = 4.3 Hz), 125.5 (qd, J CF = 270.9 Hz, J CP = 1.3 Hz), 123.67–13.60 (m), 9.7 (d, J CP = 38.8 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.8 (d, J = 4.1 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ −1.4 (s); HRMS (ESI) m/z calcd. for C 15 H 17 BF 3 NaP [M + Na] + 319.1005, found 319.1013. Colorless oil; Yield:49%, 135 mg; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.41 (s, 4H), 2.24–1.43 (br, 2H), 1.63–1.55 (m, 6H), 1.05–0.97 (m, 9H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −27.6 (d, J BP = 53.0 Hz); 13 C NMR (125 MHz, CDCl 3 ) δ 135.8 (d, J CP = 6.6 Hz), 126.5 (qd, J CF = 31.7 Hz, J CP = 4.2 Hz), 125.0 (qd, J CF = 271.6 Hz), 123.6–123.5 (m), 12.8 (d, J CP = 34.1 Hz), 6.4 (d, J CP = 3.8 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.7 (d, J FP = 3.0 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 12.8 (s); HRMS (ESI) m/z calcd. for C 13 H 21 BF 3 NaP [M + Na] + 299.1318, found 299.1319. White solid; Yield:38%, 121 mg; MP 62.0–62.3 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.75–7.70 (m, 2H), 7.61–7.52 (m, 3H), 7.39 (s,4H), 2.45–1.76 (br, 2H), 2.02–1.77 (m, 4H), 0.98–0.90 (m, 6H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −27.3 (s); 13 C NMR (125 MHz, CDCl 3 ) δ 135.9 (d, J CP = 7.1 Hz), 132.1 (d, J CP = 7.5 Hz), 131.3 (d, J CP = 2.5 Hz), 128.9 (d, J CP = 9.4 Hz), 126.8 (qd, J CF = 31.7 Hz, J CP = 4.2 Hz), 126.1 (d, J CP = 50.3 Hz), 125.0 (q, J CF = 271.5 Hz), 123.61–123.56 (m), 15.1 (d, J CP = 35.6 Hz), 6.7 (d, J CP = 3.0 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.7 (d, J = 3.8 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 13.3 (s); ESMS (ESI) m / z calcd. for C 17 H 21 BF 3 PNa [M + Na] + 347.1318, found 347.1317. White solid; Yield:13%, 123 mg (2 steps); MP 59.0–59.4 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.49 (d, J = 7.4 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 2.30–1.52 (br, 2H), 2.28–2.18 (m, 3H), 1.17–1.12 (m, 18H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.7 (d, J = 37.6 Hz,); 13 C NMR (125 MHz, CDCl 3 ) δ 136.3 (d, J CP = 6.2 Hz), 126.5 (q, J CF = 30.0 Hz), 125.1 (q, J CF = 271.4 Hz), 123.4 (s), 20.8 (d, J CP = 29.2 Hz), 18.0 (s); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.6 (d, J = 3.5 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 24.9 (s); HRMS (ESI) m/z calcd. for C 16 H 27 BF 3 NaP [M + Na] + 341.1788, found 341.1791. White solid; Yield 18%, 186 mg (2 steps); MP 94.8–95.2 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.87–7.65 (m, 2H), 7.65–7.57 (m, 3H), 7.52 (d, J = 7.1 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 2.65–2.00 (br, 2H), 2.63–2.53 (m, 2H), 1.01–0.86 (m, 12H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.9 (s); 13 C NMR (125 MHz, CDCl 3 ) δ 136.3 (d, J CP = 7.0 Hz), 133.6 (d, J CP = 6.5 Hz), 131.3 (d, J CP = 2.4 Hz), 128.6 (d, J CP = 8.7 Hz), 126.7 (qd, J CF = 31.8 Hz, J CP = 3.8 Hz), 125.0 (q, J CF = 271.2 Hz), 123.9 (s), 123.53–123.48 (m), 21.2 (d, J CP = 31.8 Hz), 16.7–16.5 (m); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.7 (d, J = 2.8 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 22.5 (s); HRMS (ESI) m/z calcd. for C 19 H 25 BF 3 NaP [M + Na] + 375.1631, found 375.1632. White solid; Yield:22%, 68 mg (2 steps); MP 72.6–72.8 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.46 (d, J = 6.9 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 1.99–1.12 (br, 2H), 0.81–0.66 (m, 15H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −29.4 (s); 13 C NMR (125 MHz, DMSO- d 6 ) δ 136.6 (d, J CP = 6.8 Hz), 125.5 (qd, J CF = 271.4 Hz), 125.4 (qd, J CF = 31.1 Hz, J CP = 4.1 Hz), 123.42–123.39 (m), 2.37 (d, J CP = 3.3 Hz), 1.65 (d, J CP = 59.3 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.6 (d, J = 4.0 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 17.7 (s); HRMS (ESI) m/z calcd. for C 16 H 21 BF 3 NaP [M + Na] + 335.1318, found 335.1321. White solid; Yield:15%, 54 mg; MP 33.2–33.8 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.41 (s, 4H), 1.59–1.52 (m, 6H), 2.10–1.48 (br, 2H), 1.38–1.29 (m, 12H), 0.85 (t, J = 7.0 Hz, 9H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −26.8 (s); 13 C NMR (125 MHz, DMSO- d 6 ) δ 136.2 (d, J CP = 6.6 Hz), 125.54 (q, J CF = 270.9 Hz), 125.48 (qd, J CF = 31.1 Hz, J CP = 4.0 Hz), 123.7–123.6 (m), 24.43 (d, J CP = 2.7 Hz), 24.37 (d, J CP = 12.5 Hz), 20.1 (d, J CP = 33.8 Hz), 13.9 (s); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.7 (s); 31 P NMR (161 MHz, DMSO- d 6 ) δ 7.4 (s); ESMS (ESI) calcd. for C 19 H 33 BF 3 PNa [M + Na] + 383.2257, found 383.2270. White solid; Yield:32%, 126 mg; MP 88.0–88.6 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.48 (d, J = 7.0 Hz, 2H), 7.38 (d, J = 7.8 Hz, 2H), 2.24–1.73 (br, 2H), 2.20–2.12 (m, 3H), 1.82–1.80 (m, 6H), 1.58–1.50 (m, 18H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.9 (s); 13 C NMR (125 MHz, CDCl 3 ) δ 136.4 (d, J CP = 6.0 Hz), 126.4 (qd, J CF = 31.6 Hz, J CP = 4.0 Hz), 125.1 (q, J CF = 271.1 Hz), 123.31–123.26 (m), 34.3 (d, J CP = 32.0 Hz), 28.4 (s), 26.1 (d, J CP = 8.4 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.9 (t, J = 2.3 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 19.4 (s); HRMS (ESI) m/z calcd. for C 22 H 33 BF 3 NaP [M + Na] + 419.2257, found 419.2247. White solid; Yield:29%, 140 mg; MP 126.7–127.0 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.47–7.40 (m, 4H), 1.98–1.10 (br, 2H), 1.93–1.65 (m, 18H), 1.32–1.20 (m, 15H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −28.8 (s); 13 C NMR (125 MHz, DMSO- d 6 ): δ 136.8 (d, J CP = 6.3 Hz), 125.5 (d, J CF = 271.7 Hz), 125.4 (qd, J CF = 31.1 Hz, J CP = 3.6 Hz), 123.6 (s), 30.4 (d, J CP = 28.7 Hz), 27.8 (s), 27.2 (d, J CP = 10.0 Hz), 26.2 (s); 19 F NMR (376 MHz, DMSO- d 6 ) δ −69.6 (d, J = 2.8 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 16.2 (s); HRMS (ESI) m/z calcd. for C 25 H 39 BF 3 ClP [M + Cl] − 473.2529, found 473.2529. White solid; Yield 37%, 132 mg, MP 52.7–53.7 °C; 1 H NMR (400 MHz, acetone- d 6 ) δ 7.54 (d, J = 7.1 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 4.27 (d, J = 357.0 Hz, 1H), 2.45–1.63 (br, 2H), 2.13–2.03 (m, 2H), 1.86–1.66 (m, 10H), 1.46–1.25 (m, 10H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −29.4 (s); 13 C NMR (100 MHz, acetone- d 6 ) δ 137.0 (d, J CP = 7.7 Hz), 126.9 (qd, J CF = 31.4 Hz, J CP = 4.1 Hz), 126.3 (qd, J CF = 270.8 Hz, J CP = 1.3 Hz), 124.3–124.2 (m), 30.1 (s), 29.8 (d, J CP = 31.3 Hz), 29.1 (s), 27.4 (d, J CP = 10.4 Hz), 27.2 (d, J CP = 11.7 Hz), 26.5 (d, J CP = 1.1 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.7 (d, J FP = 3.4 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 10.5 (d, J = 368.2 Hz); HRMS (ESI) m/z calcd. for C 19 H 29 BF 3 NaP [M + Na] + 379.1944, found 379.1964. White solid; Yield:23%, 73 mg; MP 41.1–41.6 °C; 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.48 (d, J = 7.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 2.53 (d, J = 9.1 Hz, 18H), 2.30–1.56 (br, 2H); 11 B NMR (128 MHz, DMSO- d 6 ) δ −27.2 (d, J = 102.7 Hz); 13 C NMR (125 MHz, DMSO- d 6 ): δ 136.8 (d, J CP = 7.8 Hz), 125.6 (q, J CF = 271.7 Hz), 125.3 (qd, J CF = 31.2 Hz, J CP = 3.9 Hz), 123.42–123.37 (m), 37.4 (d, J CP = 3.3 Hz); 19 F NMR (376 MHz, DMSO- d 6 ) δ −60.6 (d, J = 3.9 Hz); 31 P NMR (161 MHz, DMSO- d 6 ) δ 92.5 (s); HRMS (ESI) m/z calcd. for C 13 H 24 BF 3 N 3 KP [M + K] + 360.1385, found 360.1398. The 1-octanol/water partition coefficient P was determined using HPLC based on the OECD Guideline for Testing Chemicals. A COSMOSIL Packed Column 5C18-MS-II (5 μm, 150 mm × 4.6 mm id, Nacalai Tesque, Inc., Kyoto, Japan) was fitted on an HPLC instrument (Multiwavelength Detector, MD-2010 Plus. JASCO, Tokyo, Japan) equipped with a pump (PU-2080, JASCO) and an oven (SSC-2120, Senshu Scientific Co., Ltd., Tokyo, Japan). The injection volume was 20 µL; the mobile phase was methanol–water 75% ( v / v ); and the flow rate was 1.0 mL/min in all cases. Compounds were detected by measuring the UV absorption at 240 nm. The temperature of the column was kept at 40.0 (± 0.1) °C during the measurement. The measurement was performed in triplicate, and the mean value was calculated. The dead time t 0 was measured with thiourea as the unretained compound, and the capacity factor k was calculated using the equation log k = log (t r − t 0 /t 0 ), where t r represents the retention time of the compound. A calibration graph was determined experimentally using reference compounds (4-methylphenol, 4-chlorophenol, 4-phenylphenol, diphenylether, fluoranthene, and dichlorodiphenyltrichloroethane) with known log P values. The Log P values of phosphine–boranes were calculated based on a calibration graph (Log P = 2.6269 log k w + 3.059, R 2 = 0.9915). T47D alkaline phosphatase assays were performed as previously described, with minor modifications [ 40 ]. Briefly, the human breast cancer cell line T47D (HMS LINCS database Accession Numbers: 50541) was routinely cultivated in RPMI 1640 medium with 10% FBS at 37 °C in a 5% CO 2 humidified incubator. The cells were plated in 96-well plates and incubated overnight in a 5% CO 2 humidified incubator at 37 °C. The next day, the cells were treated with a fresh medium containing the test compound in the presence of 1 nM of progesterone and further incubated for 48 h. The medium was aspirated, and the cells were fixed with 100 μL of 1.8% formalin–PBS. The fixed cells were washed with PBS, and 100 μL of an assay buffer (1 mg/mL p -nitrophenol phosphate in diethanolamine water solution, pH 9.0) was added. The mixture was incubated at room temperature for 2 h under light-shielded conditions. The absorbance was measured at 405 nm using a DTX 880 Multimode Detector (Beckman Coulter, Brea, CA, USA). All data points were measured in triplicate, and IC 50 values were calculated from three independent experiments. PR binding affinity was assessed using a PolarScreen Progesterone Receptor Competitor Assay Kit, Green (Invitrogen, Waltham, MA, USA, A15905) based on the manufacturer’s instruction. Briefly, PR-LBD(GST)/Fluormone PR Green Complex (final concentration: 6.5 nM) and test compounds (final concentration: 100 nM to 32 μM for the phosphine-boranes and 1 nM–320 nM for P4) in the assay buffer (final volume: 32 μM) were mixed on a 384-well plate (black, polypropylene). Then, the mixture was incubated at room temperature for 1 h under shade. The fluorescence polarization value (mP) was measured at 485 nm/535 nm (excitation/emission) on a DTX 880 Multimode Detector (Beckman Coulter). The structure of the LBD of hPR was prepared from the Protein Data Bank accession number 3G8O [ 56 ]. Polar hydrogen atoms and partial atomic charges were assigned using AutoDockTools (ADT). Molecular docking was performed using AutoDock 4.2 with the genetic algorithm. The AutoDock parameters for boron atoms were Rii = 4.08 and eii = 0.180.

Phosphine–boranes are complexes of phosphines and boranes bearing P–B bonds [ 1 , 2 , 3 ]. Owing to the stability of the P–B bond in the adducts, phosphine–boranes are utilized as synthetic intermediates of phosphines: the borane moiety functions as a protective group for the oxidation-susceptible lone pair of trivalent phosphorus [ 4 , 5 , 6 ]. P–B adducts have also been investigated for biomedical applications such as boranophosphate-type nucleic acids ( 1 ), in which the P=O double bond of the phosphate moiety is replaced by a P–B bond [ 7 , 8 ]. Levin et al. developed phosphine–boranes bearing a P–BH 3 moiety, such as compound 2 , as neuroprotective agents ( Figure 1 ) [ 9 , 10 ]. From a structural arrangement perspective, the P–B substructures in phosphine–boranes can be regarded as isosteric with alkanes because of their tetrahedral sp 3 –sp 3 character. Based on this consideration, we recently developed phosphine–borane-containing estrogen receptor (ER) modulators such as 3 and 4 [ 11 , 12 ]. Subsequently, we had revealed that the P–BH 2 –Ph moiety as well as P–BH 3 moieties are useful structural options for the development of biologically active compounds, particularly for the optimization of hydrophobic substructures by controlling the hydrophobicity of the compounds. In the current study, to investigate the general usefulness of phosphine–boranes for other biological targets, we aimed to investigate the development of novel progesterone receptor (PR) antagonists based on a phosphine–borane framework. The progesterone receptor (PR) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors and plays important roles in multiple physiological processes including the female reproductive system, such as in uterine cell proliferation and differentiation, ovulation cycle, and mammary gland growth and differentiation [ 13 , 14 ]. The PR is regulated by the endogenous steroidal agonist progesterone (P4, 5 , Figure 2 ). Various steroidal PR agonists have been developed and are clinically used for the treatment of gynecological disorders, contraception, and hormone replacement therapy [ 15 , 16 ]. In addition to PR agonists, PR antagonists have attracted considerable attention as drug candidates. Although the representative, approved PR antagonist mifepristone ( 6 ) is currently in limited clinical use as an abortifacient, ulipristal acetate ( 7 ) is used not only as a contraceptive agent but also as a treatment for uterine fibroids [ 17 , 18 , 19 , 20 ]. Studies using PR antagonists, such as 6 and the investigational drug onapristone ( 8 ), indicated that PR antagonists might be effective not only for contraception and uterine fibroids but also for the treatment of endometriosis, breast cancer, ovarian cancer, uterine cancer, and some psychiatric disorders [ 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. In contrast, all PR antagonists used clinically, including 6 and 7 , are steroidal compounds. Therefore, the development of nonsteroidal PR antagonists is preferred to avoid side effects related to target selectivity and metabolic pathways. Indeed, a few steroidal PR antagonists, including 6 , demonstrate potent activities against other steroid receptors, such as the glucocorticoid receptor (GR) [ 28 , 29 , 30 ]. Thus, various nonsteroidal PR antagonists such as 10 – 13 [ 31 , 32 , 33 , 34 , 35 , 36 , 37 ] have been synthesized based on the structure of the nonsteroidal PR agonist tanaproget ( 9 ) [ 38 ]. These compounds have a common cyanoaryl moiety as the pharmacophore motif, and minor structural modifications of PR ligands bearing this motif can cause agonist/antagonist activity switching [ 32 , 33 , 38 , 39 ]. We have been investigating the development of new-generation PR antagonists and have reported that PR antagonists such as 14 and 15 are structurally distinct from conventional nonsteroidal PR antagonists ( Figure 2 ) [ 40 , 41 ]. Regarding PR antagonists and ligands of other nuclear receptors, hydrophobic interactions are essential for ligand activity. Thus, we hypothesized that the application of the phosphine–borane moiety is advantageous for the structural development of the hydrophobic moiety in PR antagonists. Consequently, we developed novel phosphine–borane framework-based PR antagonists.

To develop a novel nonsteroidal PR antagonist, we adopted the (trifluoromethyl)phenyl group as the key structural motif, which has been found to function as a pharmacophore for PR antagonists such as 14 . Our recent results indicated that the electronic profile of the B -substituents of phosphine–boranes partly influences the stability of the compounds, and an increase in the electrophilicity of the boron atom can increase the stability of the phosphine–borane adducts [ 12 ]. Thus, the introduction of an electron-withdrawing trifluoromethyl group onto the B -phenyl moiety is a reasonable approach for designing novel biologically active phosphine–borane derivatives. In addition, phosphine–borane frameworks are less hydrophobic than the corresponding carbon-based frameworks [ 11 , 12 ]; therefore, the introduction of a highly hydrophobic trifluoromethyl group on the phosphine–borane framework can provide appropriate hydrophobicity to the compounds. Regarding the phosphine moiety, various phosphines with diverse shapes and bulkiness are available because of their utility as phosphine ligands in catalysts. We assumed that the structural diversity of phosphines is particularly useful for the optimization of a hydrophobic motif in PR antagonists. Hence, we designed a series of B -(trifluoromethyl)phenyl phosphine–borane derivatives bearing a wide variety of phosphine moieties ( Figure 3 ). The designed B -(trifluoromethyl)phenyl phosphine–borane derivatives 16 – 39 were synthesized from the corresponding phosphines and 3- or 4-(trifluoromethyl)phenyl boronic acid under reductive conditions ( Scheme 1 ) [ 12 , 42 , 43 ]. Interestingly, we could obtain phosphine–borane derivatives 26 and 38 containing the P–H moiety under normal preparation conditions using an aqueous workup. We also obtained tris(dimethylamino)phosphine-borane derivatives 27 and 39 . Hydrophobicity is a key determinant of the activity and pharmacokinetics of biologically active compounds, and the octanol–water partition coefficient ( P ) and logarithm value (Log P ) are widely used hydrophobicity parameters [ 44 ]. The Log P values of the synthesized compounds were determined using HPLC [ 45 , 46 ]. Table 1 summarizes the experimentally determined Log P values and calculated values. The trimethylphosphine–borane derivatives 16 and 28 exhibited a Log P value of 3.65. In our previous study, the corresponding phenol derivative B -4-hydroxyphenyl trimethylphosphine–borane exhibited a Log P value of 2.44 [ 12 ]. The reported substituent constants of hydrophobicity of the CF 3 and phenolic OH groups were 0.88 and −0.67, respectively [ 47 ], and therefore, the difference between the Log P values of trifluoride and the corresponding phenol derivative moderately agreed with the reported difference. From the viewpoint of the phosphine structure, an increase in the number of carbon atoms increased hydrophobicity in a predictable manner. Compounds 26 and 38 bearing a P–H group and two cyclohexyl groups exhibited Log P values of 7.28 and 7.34, respectively. These Log P values were similar to those of the tri- n -butyl derivatives 23 (Log P = 7.34) and 35 (Log P = 7.50) possessing the same number of carbon atoms (C 12 ), indicating that the P–H group in the phosphine–borane derivative was almost nonpolar and did not significantly reduce the hydrophobicity of the compounds. Our previous results for B -hydroxyphenyl phosphine–borane derivatives indicated that some of these compounds showed Log P values with non-negligible differences from the calculated values. Therefore, we calculated the hydrophobicity parameters using SwissADME [ 48 , 49 ]. MLOGP is one of the most representative calculation methods of Log P defined by Moriguchi et al. [ 50 , 51 ], which is referred to as Lipinski’s Rule of Five [ 52 , 53 ]. Figure 4 A shows the correlation between the measured Log P and MLOGP values, with the exception of amide compounds 27 and 39 , which is expressed by the following equation: Log P = 1.735MOLGP − 4.093 (R 2 = 0.911). The correlation coefficient was above 0.9 but not sufficiently large, and moreover, the slope and intercept were significantly large. The difference between the calculated and measured values of each compound ranged from –0.77 ( 17 ) to +1.60 ( 37 ). MLOGP is a calculation method based on the topology of chemical structures using 13 molecular descriptors that are correlated with Log P values. Thereafter, we used the WLOGP calculation method, defined by Wildman and Crippen based on the classification of constituent atoms using 68 atomic descriptors [ 54 ]. Figure 4 B shows the correlation between the measured Log P and WLOGP values, which was expressed by the following equation: Log P = 1.016WLOGP + 0.271 (R 2 = 0.980). The correlation coefficient was close to 1.0, and the slope and intercept were smaller than those of MLOGP. These results suggest that WLOGP was more suitable for predicting the hydrophobicity of phosphine–borane derivatives. The PR agonistic and antagonistic activities of the synthesized phosphine–borane derivatives were evaluated using an alkaline phosphatase assay with the T47D human breast cancer cell line [ 55 ]. None of the test compounds induced alkaline phosphatase activity alone, indicating that they do not act as PR agonists. The basal alkaline phosphatase activity was also not affected by the tested compounds alone. The results also indicated that these compounds exhibited no significant cytotoxicity ( Figure S1 ). The PR antagonistic activities of the compounds were assessed in the presence of 1 nM of P4 ( 5 ). We also calculated the molecular volume of each compound to investigate the structure–activity relationship (SAR). Table 2 summarizes the PR antagonistic activity and calculated volumes of the synthesized compounds. All tested compounds exhibited PR antagonistic activity. Among the 3-CF 3 derivatives 16 – 27 , the trimethylphosphine derivative 16 , tri- n -butylphosphine derivative 23 , and tricyclohexylphosphine derivative 25 exhibited only weak potency, and the triethylphosphine derivative 18 , diisopropyl(phenyl)phosphine derivative 21 , and tricyclopentylphosphine derivative 24 exhibited moderate PR antagonistic activity. The dimethyl(phenyl)phosphine derivative 17 , diethyl(phenyl)phosphine derivative 19 , triisopropylphosphine derivative 20 , and tricyclopropylphosphine derivative 22 , as well as the amide derivative 27 , exhibited potent activities. These results indicate that the trimethylphosphine moiety cannot sufficiently fill the hydrophobic cavity of the ligand-binding pocket of PR and that the bulky phosphine moiety is too large to enter the ligand-binding pocket. The findings also indicated that phosphines bearing 8–10 carbon atoms are suitable for the hydrophobic substructure of the designed PR antagonists, with the tricyclopropylphosphine substructure as the most suitable hydrophobic motif. The SAR of the 4-CF 3 derivatives 28 – 39 were similar to those of 3-CF 3 derivatives, and among the synthesized compounds, B -(4-trifluoromethyl)phenyl tricyclopropylphosphine–borane ( 34 ) was the most potent with an IC 50 value of 0.54 μM. Interestingly, tricyclopropylphosphine derivative 34 was approximately three times more potent than triisopropylphosphine derivative 32 (IC 50 = 1.51 μM). The differences in the molecular volumes of these compounds resulted in large differences in potency. We investigated the binding affinity of the compounds toward the PR ligand-binding domain (LBD) using a fluorescence polarization assay system. Compound 34 exhibited significant affinity toward PR LBD, whereas the less potent compound 28 did not show the affinity, indicating that the potent antagonistic activity of 34 in the alkaline phosphatase assay was mediated by the binding to PR ( Figure 5 ). We also investigated the activity of compounds 28 and 34 toward the androgen receptor (AR) by means of cell-proliferation promoting/inhibitory activity toward androgen-dependent SC-3 cells [ 56 ]. These compounds did not affect cell growth both in the presence or absence of dihydrotestosterone, indicating that these compounds did not have AR agonistic or antagonistic activity ( Tabel S1 ). To estimate the binding mode of the developed phosphine–borane-based PR antagonists, we conducted docking simulations of tricyclopropylphosphine derivatives 22 and 34 with the X-ray crystal structure of the nonsteroidal ligand-bound form of the hPR LBD (PDB ID: 3G8O) using AutoDock 4.2 [ 57 , 58 ]. Figure 6 shows the docking models of phosphine–boranes 22 and 34 in hPR LBD. In the docked structure of B -(4-trifluoromethyl)phenyl tricyclopropylphosphine–borane ( 34 ), the tricyclopropylphosphine moiety occupied the hydrophobic cavity of the ligand-binding pocket, and the 4-(trifluoromethyl)phenyl group was located in the hydrophobic cavity on the contralateral side of the phosphine moiety. In the docked structure of the 3-trifluoromethyl isomer 22 , the tricyclopropylphosphine moiety occupied the hydrophobic cavity in the same manner as that in 34 , and the 3-(trifluoromethyl)phenyl group was located near the center of the pocket. These results indicated that the tricyclopropylphosphine moiety played an important role in ligand–receptor interactions and that the optimization of the phenyl moiety could lead to the development of novel PR antagonists with improved potency. Overall, a wide variety of phosphine structures, which are difficult to construct using carbon-based functionalities, could enable fine tuning of the hydrophobic interactions, and phosphine–boranes could be a versatile option for the structural optimization of diverse drug candidates.

To expand the utility of phosphine–boranes in medicinal chemistry, we designed and synthesized a series of B -(trifluoromethyl)phenyl phosphine–borane derivatives and investigated their hydrophobic characteristics and biological activity toward the PR. The synthesized B -(trifluoromethyl)phenyl phosphine–borane derivatives exhibited predictable Log P values. We also demonstrated that the P–H group in phosphine–borane was nonpolar. Biological evaluation revealed that all synthesized phosphine–boranes, except for the secondary phosphine derivatives, exhibited PR antagonistic activity. The potency of the compounds depended on the bulkiness of the phosphine moiety, and the tricyclopropylphosphine substructure was found to be the most suitable for the designed PR antagonists. Docking simulations suggested that the tricyclopropylphosphine moiety plays an important role in ligand–receptor interactions and that optimization of the phenyl moiety could lead to the development of novel PR antagonists with improved potency. These results support the idea that phosphine–boranes are versatile structural options in medicinal chemistry for a wide variety of drug candidates, and the developed compounds, including 22 and 34 , are promising lead compounds for further structural development of next-generation PR antagonists.